Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.
The revaluation takes into account the study results, as well as the potential for a "positive outcome" from the upcoming trial readout.
The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.
Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.
Shares of the company rose 1% in recent Wednesday trade.
Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.